{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    49,
    50,
    51,
    52,
    53,
    55,
    56,
    57,
    58,
    59,
    60,
    61,
    62,
    64,
    65,
    68,
    69,
    70,
    77,
    78,
    87,
    89,
    90
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Day of \nRandomization"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline visit"
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening period"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_5",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_5",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_daily_6",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_30",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "run-in period"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "run-in phase"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "Treatment \nPhase"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "treatment \nPhase"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "treatment Phase"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "treatment phase"
      },
      {
        "id": "rep_window_25",
        "type": "Continuous",
        "sourceText": "posttreatment period"
      },
      {
        "id": "rep_window_26",
        "type": "Continuous",
        "sourceText": "8 hours before"
      },
      {
        "id": "rep_window_27",
        "type": "Continuous",
        "sourceText": "30 days before"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P1D",
        "exitCondition": "End of treatment period",
        "sourceText": "DOSAGE AND ADMINISTRATION ... Study Drugs"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "null",
        "endOffset": "null",
        "interval": "null",
        "exitCondition": "null",
        "sourceText": "throughout treatment"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "PRETREATMENT_PHASE",
          "SCREENING",
          "DOUBLE_BLIND_TREATMENT_PHASE",
          "POST_TREATMENT_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Post-Treatment Follow-up",
          "Double-Blind Treatment Visits",
          "Screening",
          "Day 1",
          "Baseline",
          "Randomization"
        ],
        "sourceText": "[{'condition': 'Subject unable to attend scheduled visits', 'path': ['POST_RANDOMIZATION_FOLLOW_UP_FOR_PARTICIPANTS_UNABLE_TO_ATTEND_SCHEDULED_VISITS']}, {'condition': 'Subject experiences AE or renal/CV risk factor requiring discontinuation', 'path': ['EARLY_TERMINATION', 'POST_TREATMENT_FOLLOW_UP']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood \nCollection",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 1; RECURRING signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Event",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Glucose Monitoring",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3; RECURRING signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Diary",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 1; RECURRING signals: 5"
      },
      {
        "activityId": "Informed Consent",
        "executionType": "Single",
        "rationale": "Obtained once at the beginning of the study prior to any procedures."
      },
      {
        "activityId": "Screening Assessments",
        "executionType": "Single",
        "rationale": "Conducted only during the screening phase to determine eligibility."
      },
      {
        "activityId": "Safety and Efficacy Monitoring",
        "executionType": "Single",
        "rationale": "The Time and Events Schedule indicates these are performed at multiple scheduled study visits throughout the trial."
      },
      {
        "activityId": "Event-driven Outcome Collection",
        "executionType": "Single",
        "rationale": "The study is described as 'event-driven,' meaning continuous monitoring for cardiovascular and renal outcomes occurs throughout the entire study duration."
      },
      {
        "activityId": "Renal Function Monitoring (eGFR)",
        "executionType": "Single",
        "rationale": "Regularly scheduled measurements at specific study visits to monitor diabetic nephropathy progression."
      },
      {
        "activityId": "Adverse Event Reporting",
        "executionType": "Single",
        "rationale": "Continuous collection of safety data from the time of consent through the end of the study."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. EOS = end-of-study; EOT = end-of-treatment; EW=early withdrawal; HbA1c =hemoglobin A1c; CBC = complete blood count; SMBG = self-monitored blood glucose; TC = telephone contact.",
        "footnoteId": "fn_1",
        "structuredCondition": "definition_mapping",
        "appliesToActivityIds": [
          "EOS",
          "EOT",
          "EW",
          "HbA1c",
          "CBC",
          "SMBG",
          "TC"
        ],
        "sourceText": "a. EOS = end-of-study; EOT = end-of-treatment; EW=early withdrawal; HbA1c =hemoglobin A1c; CBC = com"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Subjects who fail protocol-specified screening criteria for study entry may be rescreened at the discretion of the investigator.",
        "footnoteId": "fn_2",
        "structuredCondition": "if(screening_fail, allow_rescreening(investigator_discretion))",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "b. Subjects who fail protocol-specified screening criteria for study entry may be rescreened at the "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be made to check the subject's status.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.at(W39) && timing.midpoint(office_visits, >W52)",
        "appliesToActivityIds": [
          "Telephone contact"
        ],
        "sourceText": "c. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be mad"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_at",
        "text": "d. This visit will occur at Week 52, 104, 156, 208, and 260.",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.at([W52, W104, W156, W208, W260])",
        "appliesToActivityIds": [
          "Visit"
        ],
        "sourceText": "d. This visit will occur at Week 52, 104, 156, 208, and 260."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_at",
        "text": "e. This telephone contact will occur at Week 39, 65, 91, 117, 143, 169, 195, 221, 247, and 273.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.at([W39, W65, W91, W117, W143, W169, W195, W221, W247, W273])",
        "appliesToActivityIds": [
          "Telephone contact"
        ],
        "sourceText": "e. This telephone contact will occur at Week 39, 65, 91, 117, 143, 169, 195, 221, 247, and 273."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_at",
        "text": "f. This visit will occur at Week 26, 78, 130, 182, 234 and 286.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.at([W26, W78, W130, W182, W234, W286])",
        "appliesToActivityIds": [
          "Visit"
        ],
        "sourceText": "f. This visit will occur at Week 26, 78, 130, 182, 234 and 286."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. End-of-treatment/end-of-study/early withdrawal evaluations will be performed when the double-blind treatment phase of the study is ended.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.at(end_of_double_blind_phase)",
        "appliesToActivityIds": [
          "End-of-treatment evaluations",
          "End-of-study evaluations",
          "Early withdrawal evaluations"
        ],
        "sourceText": "g. End-of-treatment/end-of-study/early withdrawal evaluations will be performed when the double-blin"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_after",
        "text": "h. A telephone follow-up contact (or optional study visit) will be conducted for all subjects approximately 30 days (+/- 12 days) after the last dose.",
        "footnoteId": "fn_8",
        "structuredCondition": "timing.after(last_dose, P30D) +/- P12D",
        "appliesToActivityIds": [
          "Telephone follow-up contact",
          "Optional study visit"
        ],
        "sourceText": "h. A telephone follow-up contact (or optional study visit) will be conducted for all subjects approx"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Analysis",
        "endpointType": "Primary",
        "inputs": [
          "Primary composite endpoint events",
          "Time to event"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "End of study"
        },
        "algorithm": "Time-to-event analysis of the primary composite endpoint",
        "successCriteria": "Statistically significant reduction in the composite endpoint events compared to placebo",
        "sourceText": "11.3.1. Primary Efficacy Analysis"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Analyses",
        "endpointType": "Secondary",
        "inputs": [
          "Secondary composite endpoint events",
          "Time to event"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "End of study"
        },
        "algorithm": "Time-to-event analysis of the secondary composite endpoint",
        "successCriteria": "Statistically significant reduction in the secondary composite endpoint events compared to placebo, adjusted for multiplicity",
        "sourceText": "11.3.2. Secondary Efficacy Analyses"
      },
      {
        "id": "ep_3",
        "name": "Primary and Secondary Composite Endpoints Adjudication",
        "endpointType": "Secondary",
        "inputs": [
          "Clinical event data",
          "Independent Endpoint Adjudication Committee (IEAC) review"
        ],
        "timeWindow": {
          "reference": "Event occurrence",
          "duration": "Adjudication period"
        },
        "algorithm": "Event confirmed by IEAC based on pre-specified criteria",
        "successCriteria": "Adjudication of events as meeting protocol-defined endpoint criteria",
        "sourceText": "9.2. Reporting/Adjudication of Events in the Primary and Secondary Composite Endpoints and Other Events for Adjudication"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from Baseline in Albumin/Creatinine Ratio",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Albumin",
          "Creatinine"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Not explicitly defined in provided text",
        "baselineVisit": "Baseline",
        "analysisWindow": "Through 01 July 2012",
        "imputationRule": "Not specified",
        "unit": "Not specified"
      },
      {
        "id": "dv_2",
        "name": "Mean Change from Baseline in eGFR",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "eGFR"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Not explicitly defined in provided text",
        "baselineVisit": "Baseline",
        "analysisWindow": "Over time (within 2 days after last study medication)",
        "imputationRule": "Not specified",
        "unit": "mL/min/1.73m2"
      },
      {
        "id": "dv_3",
        "name": "Time to first occurrence of ESKD, doubling of serum creatinine, and renal or CV death",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Randomization Date",
          "ESKD Date",
          "Serum Creatinine",
          "Renal Death Date",
          "CV Death Date"
        ],
        "derivationRule": "Date of first event (ESKD, doubling of serum creatinine, renal death, or CV death) - Date of randomization",
        "baselineDefinition": "Baseline average determination for serum creatinine",
        "baselineVisit": "Pre-randomization",
        "analysisWindow": "Up to GTED (Global Trial End Date)",
        "imputationRule": "Stratified Cox proportional hazard model",
        "unit": "Days"
      },
      {
        "id": "dv_4",
        "name": "Sustained doubling of serum creatinine",
        "variableType": "Composite",
        "sourceVariables": [
          "Serum Creatinine"
        ],
        "derivationRule": "Serum creatinine value >= 2 * baseline average determination, sustained over subsequent measurements",
        "baselineDefinition": "Average of baseline values (rather than a single value)",
        "baselineVisit": "Baseline",
        "analysisWindow": "Double-blind treatment phase",
        "imputationRule": "Not specified",
        "unit": "mg/dL or umol/L"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Pretreatment Phase",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Pretreatment Phase",
        "Screening",
        "Double Blind Treatment Phase",
        "Post Treatment Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Pretreatment Phase",
          "toState": "Screening",
          "trigger": "Progress to Screening"
        },
        {
          "fromState": "Screening",
          "toState": "Double Blind Treatment Phase",
          "trigger": "Progress to Double Blind Treatment Phase"
        },
        {
          "fromState": "Double Blind Treatment Phase",
          "toState": "Post Treatment Follow Up",
          "trigger": "Progress to Post Treatment Follow Up"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Pretreatment Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Double Blind Treatment Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Pretreatment Phase": "PRETREATMENT_PHASE",
        "Screening": "SCREENING",
        "Double Blind Treatment Phase": "DOUBLE_BLIND_TREATMENT_PHASE",
        "Post Treatment Follow Up": "POST_TREATMENT_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "Canagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 100.0,
            "unit": "mg",
            "description": "investigational product dose"
          }
        ],
        "durationDescription": "Event-driven",
        "doseModifications": [
          "Safety in renal impairment population monitored (Section 1.1.2.5.3)"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Event-driven"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_llm_1",
        "visitName": "Prescreening",
        "targetDay": -180,
        "windowBefore": 0,
        "windowAfter": 180,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Pretreatment"
      },
      {
        "id": "visit_2",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Pretreatment",
        "sourceText": "12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening. Rationale: Clarify therapy reporting for subjects wh"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "1.1.2.5.1 Overall Safety; 6.1 Study Drug; 12 Adverse Events Reporting;"
      },
      {
        "id": "visit_3",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "endpoints. Lastly, if determined medically necessary, cautionary post-baseline use of mineralocorticoid antagonist (MRA) (according to local label) will be permitted to allow subjects requiring treatm"
      },
      {
        "id": "visit_7",
        "visitName": "end of treatment",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "end of treatment/final on-site visit, 30 day telephone follow-up contact and the actual GTED. Time and Events"
      },
      {
        "id": "visit_10",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Duration of study (from first subject randomized to last end of study visit): estimated to be 60 months. Primary Efficacy Analysis"
      },
      {
        "id": "visit_4",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Double-Blind Treatment",
        "sourceText": "Randomization); 4.2. Inclusion Criteria (Criterion #2);"
      },
      {
        "id": "visit_8",
        "visitName": "Week 3",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 3,
        "sourceText": "After randomization, subjects will return to the clinic at Week 3, Week 13, Week 26, and every 26 weeks thereafter for laboratory assessments, concomitant medication review, adverse event collection a"
      },
      {
        "id": "visit_11",
        "visitName": "Week 13",
        "targetDay": 85,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 13,
        "sourceText": "Week 13 Week 26 Week 39"
      },
      {
        "id": "visit_12",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 26,
        "sourceText": "Week 26 Week 39 (TC) c"
      },
      {
        "id": "visit_9",
        "visitName": "Week 39",
        "targetDay": 267,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 39,
        "sourceText": "determination of clinical endpoints. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be made to check the subject status, including discussing study diary en"
      },
      {
        "id": "visit_13",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 52,
        "sourceText": "Week 52 and at 52- week"
      },
      {
        "id": "visit_6",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "Follow-up; 10.1. Subject Completion; Clarified the process of announcement of the predicted Global Trial End Date (GTED),"
      },
      {
        "id": "visit_14",
        "visitName": "Week 65",
        "targetDay": 449,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 65,
        "sourceText": "Week 65 and at 26- week"
      },
      {
        "id": "visit_15",
        "visitName": "Week 78",
        "targetDay": 540,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 78,
        "sourceText": "Week 78 and at 52- week"
      },
      {
        "id": "visit_16",
        "visitName": "Week 104",
        "targetDay": 722,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 104,
        "sourceText": "to Week 104 were seen in the lumbar spine (a cancellous bone region), femoral neck (a mixed cancellous and cortical bone region), and distal forearm. A decrease in BMD from baseline to Week 104 in the"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "eGFR category",
          "categories": [
            "30 to <60 mL/min/1.73m2",
            "60 to <90 mL/min/1.73m2"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "JNJ-28431754 (canagliflozin)\nClinical Protocol 28431754DNE3001 - Amendment INT-6\n11\nStatus: Approved, Date: 06 September 2017\nApplicable Section(s)\nDescription of Change(s)\nSynopsis (Secondary \nObject"
    }
  }
}